



Influenza VLPs



Universität für Bodenkultur Wien  
Department für Angewandte Genetik  
und Zellbiologie

## Marc-André D'Aoust

Vice-President, Research and Innovation  
Medicago, inc

# Development of the Next Generation Influenza Vaccine

Current influenza vaccination provides only a limited protection against the dominant virus subtype H3N2. Medicago has developed a recombinant seasonal influenza vaccine in the form of virus-like particles (VLPs) that is currently evaluated in a human efficacy study involving 10.000 subjects. The plant-based technology allows for the production of vaccines that match the circulating strains and the VLP display of antigens results in strong immune responses.

The presentation will summarize the development of our next generation influenza vaccine, emphasising on the technological platform and (pre-) clinical results.

4<sup>th</sup> Oct, 14.00, DAGZ-Seminar-room, Muthgasse 18,  
4th floor

Hosted by  
Herta Steinkellner  
Richard Strasser  
Alexandra Castilho